Skip to main content

NCT01081769 - A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater-Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmitate to Treatment as Usual With Oral Antips

A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater-Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmitate to Treatment as Usual With Oral Antipsychotic Monotherapy in Adults With Schizophrenia


CSR Summary

Not Yet Available


Primary Citation

Not Available


Data Specification

Not Available


Annotated CRF

Available upon data request approval

Data Request Dashboard

Operations

No data requests found. Click here to generate a new one.

Product Info

Generic Name
Paliperidone palmitate
Product Name
INVEGA SUSTENNA®
Therapeutic Area
Neurosciences
Enrollment
769
% Female
41.6%
% White
N/A
Product Class
Atypical Antipsychotics
Sponsor Protocol Number
R092670SCH3005
Data Holder
Johnson & Johnson
Condition Studied
Schizophrenia
Mean/Median Age (Years)
32.5

Supporting Documentation

Data Definition Specification Available
Annotated Case Report Form Available
Clinical Study Report
Collected Datasets
Protocol with Amendments
Study Phase 
3

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.